An aminoquinolone with antimalarial and anti-inflammatory activities
Hydroxychloroquine sulfate is a synthetic antimalarial drug which can also inhibit Toll-like receptor 7/9 (TLR7/9) signaling.
Hydroxychloroquine sulfate is a synthetic antimalarial drug derived from 4-aminoquinoline; it has been used for several decades for the treatment of some rheumatic diseases such as rheumatoid arthritis (RA)[1]. Five micromolar Hydroxychloroquine sulfate or chloroquine also has no measurable effect on intracellular pH, although these concentrations can inhibit TLR9 or 7 signaling induced by DNA or RNA ligands[2].
Hydroxychloroquine sulfate is prescribed for the treatment of lupus, and both Hydroxychloroquine sulfate and its analog chloroquine inhibit TLR7 and 9 signaling[2]
硫酸羟氯喹是一种合成的抗疟药物，也可以抑制Toll样受体7/9（TLR7/9）信号传导。硫酸羟氯喹是从4-氨基喹啉衍生出来的合成抗疟药物，已经用于治疗风湿性疾病如类风湿性关节炎等几十年[1]。5微摩尔的硫酸羟氯喹或氯喹对细胞内pH没有可测的影响，但这些浓度可以抑制DNA或RNA配体引起的TLR9或7信号传导[2]。硫酸羟氯喹被用于治疗狼疮，而硫酸羟氯喹及其类似物氯喹均能抑制TLR7和9信号[2]。
Reference:
[1]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6.
[2]. Lamphier M, et al. Novel small molecule inhibitors of TLR7 and TLR9: mechanism of action and efficacy in vivo. Mol Pharmacol. 2014 Mar;85(3):429-40.
Kinase experiment: | Five microliters of a solution of 2% L-α-phosphatidylcholine in dodecane is deposited per well on membranes of a 96-well plate. AT791 (10 μM), E6446 (10 μM), Hydroxychloroquine sulfate (40 μM), or chloroquine (40 μM) are added to one of the two compartments in pH 5.5 buffer (50 mM NaAce, 15 mM NaCl) or pH 7.4 buffer (50 mM KPO4, 150 mM NaCl), and the plate is incubated at 37°C. The next day, compound concentrations in both chambers are quantitated. In one variation of this experiment, 5 μM AT791 or E6446 is added to both chambers, one of which contains pH 5.5 buffer and the other pH 7.4 buffer. The redistribution of compound between the two chambers is monitored for 8 hours[2]. |
Animal experiment: | MRL/lpr mice are dosed orally five times a week with 20 or 60 mg/kg E6446 or 60 mg/kg Hydroxychloroquine sulfate beginning at 5 weeks of age. Cytoxan is administered at 50 mg/kg i.p. every 10 days. A serum sample is taken immediately before the beginning of treatment to monitor changes in autoreactive antibodies. Subsequently, serum samples are collected approximately monthly and analyzed for anti-dsDNA by ELISA after 1:500 dilution. Body weights and urine samples are taken at the same interval, and proteinuria is assessed. Anti-nuclear antibodies (ANA) are assessed using commercially available HEp2 slide kits, with serum diluted to 1:100 in kit buffer. ANA scores are read blinded[2]. |
参考文献: [1]. Manzo C, et al. Psychomotor Agitation Following Treatment with Hydroxychloroquine. Drug Saf Case Rep. 2017 Dec;4(1):6. | |
动态评分
0.0